FFP104: Phase II started

Fast Forward began an open-label, dose-escalation, European Phase II trial to evaluate 1, 2.5 and 5 mg/kg IV FFP104 weekly or biweekly for 12 weeks in about 24 patients. Fast Forward exclusively licen...